Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00200382

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00200382. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.

Study identification

NCT ID: NCT00200382
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Rasim Gucalp; Other
Enrollment: 27 participants

Conditions and interventions

Conditions

Non-small Cell Lung Cancer

Interventions

PS-341 (Velcade-drug) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2004 (Actual)
Primary completion: May 2007 (Actual)
Completion: May 2007 (Actual)
Last update posted: Aug 2, 2018

2004 – 2007

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
HealthAlliance Hospitals	Fitchburg	Massachusetts	01420	—
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
Albert Einstein Cancer Center	The Bronx	New York	10461	—
Jacobi Medical Center	The Bronx	New York	10461	—
Montefiore Medical Center	The Bronx	New York	10467	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00200382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 2, 2018 · Synced Nov 15, 2026